374Water Demonstrates Effectiveness of AirSCWO in Destroying Pharmaceutical Waste
374Water Inc. (Nasdaq:SCWO) has successfully demonstrated the effectiveness of its AirSCWO technology in destroying pharmaceutical waste for a major manufacturer. The demonstration achieved >99.9% destruction of halogenated solvents and organic wastes, surpassing the 99.5% efficiency of on-site incineration. AirSCWO eliminated organics to levels ten times lower than discharge limits for on-site injection.
The technology offers a sustainable solution for the $40 billion global pharmaceutical waste management market, addressing challenges such as environmental contamination and regulatory compliance. AirSCWO transforms organic waste into harmless water and minerals, potentially creating additional value through rare earth material recovery. CEO Chris Gannon highlighted the technology's capability to handle diverse and complex waste streams, positioning it as an effective alternative to conventional off-site disposal methods.
374Water Inc. (Nasdaq:SCWO) ha dimostrato con successo l'efficacia della sua tecnologia AirSCWO nella distruzione dei rifiuti farmaceutici per un importante produttore. La dimostrazione ha raggiunto una destuzione superiore al 99,9% di solventi alogenati e rifiuti organici, superando l'efficienza del 99,5% dell'incenerimento in loco. AirSCWO ha ridotto gli organici a livelli dieci volte inferiori ai limiti di scarico per l'iniezione in loco.
La tecnologia offre una soluzione sostenibile per il mercato globale della gestione dei rifiuti farmaceutici da 40 miliardi di dollari, affrontando sfide come la contaminazione ambientale e la conformità normativa. AirSCWO trasforma i rifiuti organici in acqua e minerali innocui, creando potenzialmente un ulteriore valore attraverso il recupero di materiali rari. Il CEO Chris Gannon ha sottolineato la capacità della tecnologia di gestire flussi di rifiuti diversi e complessi, posizionandola come un'alternativa efficace ai metodi tradizionali di smaltimento off-site.
374Water Inc. (Nasdaq:SCWO) ha demostrado con éxito la efectividad de su tecnología AirSCWO para destruir desechos farmacéuticos para un importante fabricante. La demostración logró una distrucción superior al 99,9% de solventes halogenados y desechos orgánicos, superando la eficiencia del 99,5% de la incineración en sitio. AirSCWO eliminó organicos a niveles diez veces inferiores a los límites de descarga para la inyección en sitio.
La tecnología ofrece una solución sostenible para el mercado global de gestión de desechos farmacéuticos de 40 mil millones de dólares, abordando desafíos como la contaminación ambiental y el cumplimiento normativo. AirSCWO transforma los desechos orgánicos en agua y minerales inofensivos, creando potencialmente un valor adicional a través de la recuperación de materiales raros. El CEO Chris Gannon destacó la capacidad de la tecnología para manejar flujos de desechos diversos y complejos, posicionándola como una alternativa efectiva a los métodos tradicionales de eliminación fuera del lugar.
374Water Inc. (Nasdaq:SCWO)는 주요 제조업체를 위해 약물 폐기물 파괴에 있어 AirSCWO 기술의 효과를 성공적으로 입증하였습니다. 이 시연에서 99.9% 이상의 파괴율을 달성했으며, 이는 현장 소각의 99.5% 효율성을 능가합니다. AirSCWO는 조직을 배출 한계보다 10배 낮은 수준으로 줄였습니다.
이 기술은 400억 달러 규모의 글로벌 제약 폐기물 관리 시장을 위한 지속 가능한 솔루션을 제공하며, 환경 오염 및 규제 준수와 같은 도전 과제를 다룹니다. AirSCWO는 유기 폐기물을 무해한 물과 미네랄로 전환하며, 희귀 광물 회수를 통해 추가 가치를 창출할 잠재력이 있습니다. CEO 크리스 가논은 이 기술이 다양한 복합 폐기물을 처리할 수 있는 능력을 강조하며, 전통적인 오프사이트 폐기 방법에 대한 효과적인 대안으로 위치시키고 있습니다.
374Water Inc. (Nasdaq:SCWO) a démontré avec succès l'efficacité de sa technologie AirSCWO dans la destruction des déchets pharmaceutiques pour un grand fabricant. La démonstration a atteint une détruction supérieure à 99,9% des solvants halogénés et des déchets organiques, dépassant l'efficacité de 99,5% de l'incinération sur site. AirSCWO a éliminé les organiques à des niveaux dix fois inférieurs aux limites de décharge pour l'injection sur site.
Cette technologie offre une solution durable pour le marché mondial de la gestion des déchets pharmaceutiques de 40 milliards de dollars, répondant à des défis tels que la contamination environnementale et la conformité réglementaire. AirSCWO transforme les déchets organiques en eau et minéraux inoffensifs, créant potentiellement une valeur ajoutée grâce au recyclage de matériaux rares. Le PDG Chris Gannon a souligné la capacité de la technologie à gérer des flux de déchets divers et complexes, la positionnant comme une alternative efficace aux méthodes traditionnelles d'élimination hors site.
374Water Inc. (Nasdaq:SCWO) hat erfolgreich die Wirksamkeit seiner AirSCWO Technologie bei der Zerstörung von Pharmaabfällen für einen großen Hersteller demonstriert. Die Demonstration erreichte eine Zerstörung von über 99,9% bei halogenierten Lösungsmitteln und organischen Abfällen, was die 99,5% Effizienz der Vor-Ort-Verbrennung übertrifft. AirSCWO reduzierte organische Materialien auf Werte zehnmal unterhalb der Entsorgungsgrenzen für die Vor-Ort-Injektion.
Die Technologie bietet eine nachhaltige Lösung für den 40 Milliarden Dollar großen globalen Markt für Pharmaabfall-Management und geht Herausforderungen wie Umweltverschmutzung und regulatorischer Compliance nach. AirSCWO wandelt organische Abfälle in harmlose Wasser und Mineralien um und hat das Potenzial, zusätzlichen Wert durch die Rückgewinnung seltener Materialien zu schaffen. CEO Chris Gannon betonte die Fähigkeit der Technologie, unterschiedliche und komplexe Abfallströme zu behandeln, und positioniert sie als effektive Alternative zu herkömmlichen externen Entsorgungsmethoden.
- Achieved >99.9% destruction of halogenated solvents and organic wastes
- Eliminated organics to levels ten times lower than discharge limits
- Demonstrated effectiveness in handling diverse and mixed waste streams
- Positioned as a sustainable alternative to off-site incineration
- Addresses a $40 billion global pharmaceutical waste management market
- None.
Insights
As an environmental engineer, I'm impressed by the performance of 374Water's AirSCWO technology in treating pharmaceutical waste. The >99.9% destruction rate of halogenated solvents and organic wastes is remarkable, surpassing the industry standard of 99.5% for on-site incineration. This level of efficiency addresses a critical environmental challenge in pharmaceutical manufacturing.
The ability to reduce contaminants to levels ten times lower than discharge limits for on-site injection is a game-changer. It not only ensures regulatory compliance but also significantly reduces the risk of environmental contamination. The technology's versatility in handling diverse waste streams is particularly noteworthy, as pharmaceutical waste compositions can vary greatly.
From an environmental perspective, the most promising aspect is the potential to eliminate secondary pollutants typically associated with traditional treatment methods. By transforming organic waste into harmless water and minerals, AirSCWO could dramatically reduce the industry's environmental footprint. The possibility of recovering rare earth materials from the mineral stream adds an exciting circular economy dimension to this technology.
However, it's important to note that while the results are promising, full-scale implementation and long-term performance data will be important to fully assess the technology's environmental impact and sustainability in real-world applications.
From a financial perspective, 374Water's successful demonstration of AirSCWO technology in pharmaceutical waste treatment opens up significant market opportunities. The global pharmaceutical waste management market, valued at over
The technology's ability to achieve high destruction rates while potentially reducing operational costs is a strong value proposition. By eliminating the need for off-site incineration, pharmaceutical manufacturers could see significant cost savings in waste management, which could drive adoption of AirSCWO systems.
However, investors should consider several factors:
- The technology is not yet fully commercialized, which implies future capital expenditures and potential delays in revenue generation.
- Market penetration may be gradual, as the pharmaceutical industry often requires extensive validation before adopting new technologies.
- The potential for recovering valuable rare earth materials could provide an additional revenue stream, but this aspect is still in the R&D phase.
While the demonstration results are promising, 374Water's financial success will depend on its ability to scale up production, navigate regulatory approvals and effectively market its technology to a traditionally conservative industry. The company's future financial performance will be closely tied to its commercialization timeline and adoption rate within the pharmaceutical sector.
As a pharmaceutical industry expert, I see 374Water's AirSCWO technology as a potential breakthrough in addressing one of our sector's most pressing challenges. The pharmaceutical industry has long grappled with the environmental impact of its waste streams, particularly the presence of active pharmaceutical ingredients (APIs) in wastewater.
The demonstrated >99.9% destruction rate of organic compounds, including halogenated solvents, is particularly impressive. These compounds are notoriously difficult to treat and pose significant environmental risks. The ability to handle variable mixtures of waste streams is also crucial, as pharmaceutical manufacturing processes often produce complex and changing waste compositions.
However, several considerations are important for industry adoption:
- Regulatory compliance: While the technology exceeds current standards, it will need to meet stringent pharmaceutical industry regulations.
- Scalability: The industry will need to see evidence of consistent performance at commercial scale.
- Integration: The technology must seamlessly integrate into existing manufacturing processes without disrupting production.
- Cost-effectiveness: Long-term operational costs must be competitive with current waste management methods.
If 374Water can address these points, their AirSCWO technology could revolutionize pharmaceutical waste management, offering a more sustainable and potentially cost-effective solution. This could significantly enhance the industry's environmental profile and help mitigate the growing concern of pharmaceutical pollution in aquatic environments.
DURHAM, NC / ACCESSWIRE / July 25, 2024 / 374Water Inc. (Nasdaq:SCWO), a global leader in organic waste destruction technology for the municipal, federal, and industrial markets, has achieved another significant milestone with the successful destruction of pharmaceutical waste for a pharmaceutical manufacturer. This demonstration further highlights the versatility and robustness of 374Water's cutting-edge AirSCWO in treating complex waste streams.
Demonstration Highlights:
A pharmaceutical manufacturer requested a SCWO demonstration for wastewater treatment.
The goal was to achieve significant volume reduction to lower costs and meet local publicly owned treatment works (POTW) limits.
AirSCWO achieved >
99.9% destruction of halogenated solvents and organic wastes.
Challenge:
Advances in the pharmaceutical industry have improved health outcomes, but challenges remain in disposing of waste streams produced during manufacturing. Untreated or improperly treated pharmaceutical waste poses significant risks and liabilities, including environmental contamination and legal consequences. Active pharmaceutical ingredients (APIs) in the waste can harm aquatic life and potentially enter drinking water supplies, posing serious health risks. Proper treatment and disposal of pharmaceutical wastewater are crucial to mitigate these risks and protect both the environment and public health.
A major pharmaceutical manufacturer faced a significant challenge in managing complex waste streams with high concentrations of APIs. The company sought to modernize its waste management practices, moving away from risky and expensive off-site incineration. As 374Water plans to offer its AirSCWO system for onsite destruction at customer locations and has previously shown high elimination efficiency of other organic compounds it was considered a candidate as a suitable alternative.
Solution:
Treatability testing was performed on the manufacturer's waste using 374Water's AirSCWO (Supercritical Water Oxidation) process. The study aimed to determine the efficacy of AirSCWO in eliminating organic compounds and its ability to handle variable mixtures of waste streams. Four organic waste samples were provided, which varied in calorific content and had high concentrations of dichloromethane and other halogenated solvents. Two blends were developed to represent typical waste streams with contaminant levels exceeding regulatory limits, with the goal of future on-site destruction using AirSCWO, once 374Water's technology is fully commercialized.
Results:
Treatment using AirSCWO was successful for both blends. Using Chemical oxygen demand (COD) measurement as a proxy for all organics, AirSCWO eliminated organics to levels ten times lower than discharge limits for on-site injection. Total organic compound destruction ranged from
Innovative Approach and Benefits:
Pharmaceutical pollution, especially in regions with high concentrations of drug manufacturing, is a growing concern due to untreated wastewater containing APIs contaminating aquatic environments. 374Water believes that AirSCWO is uniquely positioned to address these wastes without producing harmful byproducts. Unlike traditional methods that often result in secondary pollutants and additional costs, AirSCWO transforms organic waste into harmless water and minerals, significantly reducing environmental impact. With ongoing R&D, the mineral stream produced by SCWO technology could potentially create additional value through the recovery of valuable rare earth materials used as catalysts in the pharmaceutical industry.
Market Opportunity:
The pharmaceutical waste management industry has a global market size exceeding
"This study showcases another successful application of our AirSCWO technology, emphasizing our capability to handle diverse and complex waste streams, particularly in the pharmaceutical sector where waste management is a significant challenge," said Chris Gannon, CEO of 374Water. "During testing, our technology not only met but exceeded regulatory effluent mandates, which we believe positions it as a sustainable and effective solution for pharmaceutical waste management and a viable alternative to conventional off-site disposal methods."
About 374Water
374Water Inc. (Nasdaq:SCWO) is a global cleantech company providing innovative solutions addressing wastewater treatment and waste management issues within the municipal, federal and industrial markets. 374Water's AirSCWO technology efficiently destroys a range of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. 374Water's AirSCWO technology has the potential to assist its customers to meet discharge requirements, reduce or eliminate disposal costs, remove bottlenecks, and reduce litigation and other risks. 374Water continues to be a leader in innovative waste treatment solutions, dedicated to creating a greener future and eradicating harmful pollutants. Learn more by visiting www.374water.com and follow us on LinkedIn.
Cautionary Language on Forward-Looking Statements
Certain statements in this communication are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements relate to future events or our future financial performance, including statements relating to our ability to execute on our strategic plan and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or our achievements or those of our industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements may be identified by the use of words like "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "project," "consider," "predict," "potential," "feel," or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates, beliefs, and projections. While the Company believes these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, as well as the Company's subsequent filings with the SEC, may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements herein are made only as of the date they were first issued, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Heather Crowell
ir@374water.com
Media Contacts:
Candace McPhillips
media@374water.com
SOURCE: 374Water Inc.
View the original press release on accesswire.com
FAQ
What destruction efficiency did 374Water's AirSCWO achieve for pharmaceutical waste?
How does 374Water's AirSCWO technology compare to discharge limits for pharmaceutical waste?
What is the market size for pharmaceutical waste management that 374Water (SCWO) is targeting?
How does 374Water's AirSCWO technology transform pharmaceutical waste?
